Michael Nally - 26 Feb 2026 Form 3 Insider Report for Generate Biomedicines, Inc. (GENB)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Wolf
Issuer symbol: GENB
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 26 Feb 2026, 21:11:27 UTC
Previous filing: 15 Dec 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nally Michael	Chief Executive Officer, Director	GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE	/s/ Michael Wolf	26 Feb 2026	0001763945

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GENB	Common Stock						552,707	26 Feb 2026	Direct
holding	GENB	Common Stock						658,327	26 Feb 2026	By MTN 2024 GST Trust	F1
holding	GENB	Common Stock						999,793	26 Feb 2026	By MTN 2024 GRAT	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	GENB	Series A Preferred Stock							26 Feb 2026	Common Stock	658,327		By MTN 2024 GST Trust	F1, F2
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	2,210,829	$0.3400	Direct	F3
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	631,665	$0.3400	Direct	F3
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	315,832	$0.3400	Direct	F3
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	572,745	$7.19	Direct	F4
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	526,662	$7.25	Direct	F5
holding	GENB	Stock Option (Right to Buy)							26 Feb 2026	Common Stock	658,327	$9.15	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2	Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-1.5190 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
F3	The shares underlying this option are fully vested and exercisable.
F4	The shares underlying this option vest in sixteen equal quarterly installments following September 1, 2023, subject to the Reporting Person's continued service on each such vesting date.
F5	The shares underlying this option vest in sixteen equal quarterly installments following January 3, 2024, subject to the Reporting Person's continued service on each such vesting date.
F6	25% of the shares underlying this option shall vest on March 1, 2026 with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney